Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
OBJECTIVES:
I. Evaluate the long-term safety and tolerance of a synthetic formulation of
dehydroepiandrosterone, GL701, in patients with systemic lupus erythematosus who have
completed a prior GL701 protocol.